The global pyrogen testing market is poised for significant growth, driven by the increasing adoption of pyrogen testing across healthcare applications, the development of innovative drugs, the launch of biologics, and continued expansion of the pharmaceutical and biotechnology industries. According to Transparency Market Research’s report covering the historical period of 2017–2018 and forecast period of 2019–2027, the market was valued at US$742.0 million in 2018 and is projected to expand at a CAGR of 12.2% between 2019 and 2027.
Introduction of Pyrogen Testing Across Applications
Pyrogen testing is widely utilized in pharmaceutical, biotechnology, and medical device industries to help ensure the safety and quality of healthcare products. Testing for pyrogens, including bacterial endotoxins, is an important component of quality-control processes for medicines, drugs, immunological products, and medical devices.
The growing emphasis on product safety, regulatory compliance, efficient manufacturing, and appropriate utilization of resources is supporting demand for pyrogen testing solutions. These tests help manufacturers identify substances capable of producing fever-inducing reactions and contribute to maintaining quality standards throughout healthcare product development and manufacturing.
Regulatory organizations have also played an important role in standardizing endotoxin testing. According to the U.S. Food and Drug Administration, the Center for Devices and Radiological Health adopted the USP Endotoxin Reference Standard, supporting standardized approaches to endotoxin testing.
Innovative Drugs and Biologics Support Market Growth
The expanding pipeline of innovative medicines is another major factor expected to contribute to the growth of the pyrogen testing market. Pharmaceutical and biotechnology companies are investing heavily in research and development, while the launch of biologic products is creating additional requirements for reliable safety and quality testing.
The growing number of new drug candidates, increasing pharmaceutical production, and higher expenditure on new product development are expected to generate opportunities for pyrogen testing providers. As manufacturers advance products through development and commercialization, testing requirements become increasingly important for demonstrating product quality and meeting applicable regulatory standards.
Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=54678
Shift Away From Rabbit Pyrogen Testing
Despite positive growth prospects, changes in testing practices may affect demand for traditional rabbit pyrogen testing. The European Pharmacopoeia has promoted the monocyte activation test (MAT) as a suitable approach for pyrogen testing and has raised concerns regarding the limitations of the traditional rabbit pyrogen test (RPT).
The shift toward alternative, non-animal testing methods is therefore expected to influence the market landscape. MAT and other innovative testing technologies could gain greater adoption as pharmaceutical and biotechnology companies seek testing approaches that align with evolving scientific and regulatory expectations.
Competitive Landscape
The global pyrogen testing market is highly fragmented, with international and regional companies competing across different product and service segments. Key participants identified in the market include Thermo Fisher Scientific, Associates of Cape Cod, Merck KGaA, Charles River Laboratories International, GenScript, Lonza Group, Sanquin, WuXi AppTec, Hyglos GmbH (a bioMérieux company), and Wako Chemicals USA, among others.
Companies are focusing on regulatory approvals, technologically advanced testing products, new product launches, acquisitions, and strategic collaborations to strengthen their market positions.
Key Industry Developments
Strategic acquisitions have also shaped the competitive environment. In July 2017, Thermo Fisher Scientific acquired Linkage Biosciences, strengthening its transplant diagnostics business and expanding its services to transplant centers worldwide.
In April 2018, Charles River Laboratories International acquired MPI Research, a non-clinical contract research organization serving biopharmaceutical and medical device companies. The acquisition expanded Charles River’s capabilities and biotechnology customer base.
Overall, increasing pharmaceutical innovation, expanding biologics development, regulatory emphasis on product safety, and technological advances in pyrogen testing are expected to remain important factors influencing the global market through the forecast period.
Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453